treprostinil
Orphan DrugFDA Approved
Description
Treprostinil is a prostacyclin analogue used for the treatment of pulmonary arterial hypertension. It works by dilating blood vessels in the lungs and inhibiting platelet aggregation. It is available in multiple formulations including continuous subcutaneous, intravenous, and inhaled routes.
Indications & Therapeutic Use
pulmonary arterial hypertension, WHO Group 1 pulmonary hypertension
Linked Diseases:
pulmonary hypertension
D006976
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
treprostinil
| Generic Name | treprostinil |
| Brands | 1 brand available |
| Active Ingredient | treprostinil sodium |
| Drug Class | pulmonary arterial hypertension |
| Manufacturer | United Therapeutics |
| Dosage Forms | subcutaneous/IV infusion 1mg/mL, 2.5mg/mL, 5mg/mL, 10mg/mL; inhalation solution |
| Medical Code | B01AC21 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00125814 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes